Behavioral health company LifeStance Health (NASDAQ:LFST) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 26.1% year on year to $435.4 million. Guidance for next quarter’s revenue was optimistic at $430 million at the midpoint, 2.9% above analysts’ estimates. Its GAAP profit of $0.06 per share was $0.03 above analysts’ consensus estimates.
Is now the time to buy LifeStance Health Group? Find out by accessing our full research report, it’s free.
LifeStance Health Group (LFST) Q2 CY2026 Highlights:
- Revenue: $435.4 million vs analyst estimates of $414.6 million (26.1% year-on-year growth, 5% beat)
- EPS (GAAP): $0.06 vs analyst estimates of $0.03 ($0.03 beat)
- Adjusted EBITDA: $66.04 million vs analyst estimates of $54.18 million (15.2% margin, 21.9% beat)
- The company lifted its revenue guidance for the full year to $1.71 billion at the midpoint from $1.66 billion, a 2.7% increase
- EBITDA guidance for the full year is $225 million at the midpoint, above analyst estimates of $210.8 million
- Operating Margin: 7%, up from -0.9% in the same quarter last year
- Free Cash Flow Margin: 20.2%, up from 16.4% in the same quarter last year
- Sales Volumes rose 10.8% year on year, in line with the same quarter last year
- Market Capitalization: $4.02 billion
“This was an outstanding second quarter and first half of 2026 for LifeStance, as we delivered quarterly revenue growth of 26%, positive net income of $24 million, and Adjusted EBITDA margins of 15%.” said Dave Bourdon, CEO of LifeStance.
Company Overview
With over 6,600 licensed mental health professionals treating more than 880,000 patients annually, LifeStance Health (NASDAQ:LFST) provides outpatient mental health services through a network of clinicians offering psychiatric evaluations, psychological testing, and therapy across 33 states.
Revenue Growth
A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, LifeStance Health Group grew its sales at an excellent 24.8% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. LifeStance Health Group’s annualized revenue growth of 17.1% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. 
We can dig further into the company’s revenue dynamics by analyzing its number of clinicians, which reached 8,542 in the latest quarter. Over the last two years, LifeStance Health Group’s clinicians averaged 10.3% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. 
This quarter, LifeStance Health Group reported robust year-on-year revenue growth of 26.1%, and its $435.4 million of revenue topped Wall Street estimates by 5%. Company management is currently guiding for a 18.2% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 12.2% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is admirable and suggests the market sees success for its products and services.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
Adjusted Operating Margin
LifeStance Health Group was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 3.4% was weak for a healthcare business.
On the plus side, LifeStance Health Group’s adjusted operating margin rose by 11.1 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company’s trajectory is intact as its margin has also increased by 8.8 percentage points on a two-year basis.
In Q2, LifeStance Health Group generated an adjusted operating margin profit margin of 11.6%, up 5.8 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
LifeStance Health Group’s full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it’s at a critical moment in its life.
In Q2, LifeStance Health Group reported EPS of $0.06, up from negative $0.01 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects LifeStance Health Group’s full-year EPS to grow 31.6% from $0.13 to $0.17.
Key Takeaways from LifeStance Health Group’s Q2 Results
It was good to see LifeStance Health Group beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this quarter featured some important positives. The stock traded up 3% to $10.68 immediately following the results.
LifeStance Health Group put up rock-solid earnings, but one quarter doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).